Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06078878

Clinical Feasibility Evaluation of the Gentuity HF-OCT Imaging System With Vis-M Micro-Imaging Catheter

This study is a prospective, single arm, unblinded, and open-label study. The study is designed to evaluate the use of the Gentuity Neurovascular Imaging System in patients undergoing elective neurointerventional diagnostic procedures.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Patients undergoing elective, neurointerventional procedures, or patient undergoing follow-up diagnostic procedures who meet all inclusion criteria and none of the exclusion criteria will be considered for enrollment. The study investigates the use of the Gentuity Neurovascular Imaging System as a diagnostic tool for intravascular imaging in the cerebrovasculature. The study evaluates the incidence and severity of device-related adverse events, clinical usability performance and technical performance of imaging quality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are electively scheduled for either a follow-up cerebral angiogram or a diagnostic angiogram and may be candidates for a neuroendovascular procedure
  • Patients that present with a Modified Rankin Score (mRS) ≤3
  • Patients 18 years of age or older
  • Patients willing and able to provide written informed consent to participate in evaluation

Exclusion criteria

  • Patients with serious concurrent medical conditions including bacteremia or sepsis, acute renal failure at the time of the procedure, and major coagulation system abnormalities that in the opinion of the investigator could significantly increase risk
  • Pregnant
  • Patient has a known hypersensitivity to contrast media
  • Patients undergoing an urgent or emergent neurointerventional procedure
  • Patients that present with a Modified Rankin Score (mRS) ≥4
  • Patients that present with an unresolved spontaneous subarachnoid hemorrhage and/or intracranial hemorrhage
  • Participation in another clinical trial of an investigational drug or device
  • Patient has existing Flow Re-Direction Endoluminal Device (FRED®) System

Treatment and study plan

HF-OCT Imaging System with Vis-M Micro-Imaging Catheter

Device

Subjects undergo HF-OCT imaging of the desired intravascular segement

Primary outcomes

  1. Device Safety

    Time frame: 7 days

    Incidence and severity of device-related adverse events.

Secondary outcomes

  1. Clinical performance

    Time frame: 1 day

    Operator evaluation of performance via Likert scale.

  2. Technical performance

    Time frame: 1 day

    Clear image length (CIL) of the vessel

Study contacts

Contact information is provided by the study sponsor or research team.

Arjun Bhat, MD, MBA

CONTACT

[email protected]

(978) 202-4108

Sharon Timberlake, MSHS

CONTACT

[email protected]

(617) 957-1434

Sponsors and collaborators

Lead sponsor

Gentuity, LLC

Industry

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Oct 12, 2023
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.